Harbor Capital Advisors Inc. Cuts Position in DexCom, Inc. (NASDAQ:DXCM)

Harbor Capital Advisors Inc. decreased its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 39.0% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,683 shares of the medical device company’s stock after selling 1,718 shares during the period. Harbor Capital Advisors Inc.’s holdings in DexCom were worth $209,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in DXCM. Thoroughbred Financial Services LLC purchased a new position in shares of DexCom during the 2nd quarter valued at about $211,000. Envestnet Asset Management Inc. raised its stake in shares of DexCom by 0.6% during the second quarter. Envestnet Asset Management Inc. now owns 599,303 shares of the medical device company’s stock worth $67,949,000 after acquiring an additional 3,356 shares in the last quarter. Massachusetts Financial Services Co. MA lifted its holdings in shares of DexCom by 16.9% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 2,439,033 shares of the medical device company’s stock worth $276,538,000 after acquiring an additional 353,019 shares during the last quarter. Dimensional Fund Advisors LP lifted its holdings in shares of DexCom by 41.3% in the 2nd quarter. Dimensional Fund Advisors LP now owns 919,650 shares of the medical device company’s stock worth $104,282,000 after acquiring an additional 268,802 shares during the last quarter. Finally, GDS Wealth Management boosted its stake in shares of DexCom by 41.7% in the 2nd quarter. GDS Wealth Management now owns 54,770 shares of the medical device company’s stock valued at $6,210,000 after purchasing an additional 16,128 shares in the last quarter. Institutional investors own 97.75% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have issued reports on DXCM. Royal Bank of Canada cut their price target on shares of DexCom from $120.00 to $115.00 and set an “outperform” rating for the company in a research report on Friday, October 25th. Oppenheimer dropped their target price on DexCom from $115.00 to $105.00 and set an “outperform” rating for the company in a report on Friday, October 25th. Canaccord Genuity Group lifted their price target on DexCom from $89.00 to $99.00 and gave the stock a “buy” rating in a research note on Monday, December 9th. Wells Fargo & Company boosted their price objective on DexCom from $90.00 to $94.00 and gave the company an “overweight” rating in a research report on Wednesday, December 11th. Finally, Leerink Partners cut their target price on shares of DexCom from $90.00 to $87.00 and set an “outperform” rating on the stock in a report on Friday, October 25th. Seven equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $98.00.

Insiders Place Their Bets

In other news, EVP Sadie Stern sold 4,259 shares of the business’s stock in a transaction that occurred on Wednesday, November 20th. The stock was sold at an average price of $74.73, for a total value of $318,275.07. Following the sale, the executive vice president now directly owns 71,192 shares of the company’s stock, valued at $5,320,178.16. The trade was a 5.64 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 0.30% of the stock is owned by corporate insiders.

DexCom Stock Down 0.8 %

Shares of NASDAQ:DXCM opened at $79.17 on Wednesday. The company has a debt-to-equity ratio of 1.23, a quick ratio of 2.12 and a current ratio of 2.46. DexCom, Inc. has a 52-week low of $62.34 and a 52-week high of $142.00. The firm has a market capitalization of $30.92 billion, a P/E ratio of 47.41, a P/E/G ratio of 2.36 and a beta of 1.12. The stock has a 50 day moving average price of $77.33 and a 200-day moving average price of $78.35.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.